Patient P-02253
Synthetic patientMETA-24 · Day 160 · 35–44 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Unstable
Tolerance
Stable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
85%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 47 NP-02 recommended — Dietary Support Protocol NP-02
- Day 48 Patient accepted — Started NP-02 in the companion
- Day 58 No meaningful change — Dietary Support Protocol NP-02
- Day 67 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 80 GI-04 recommended — GI Support Protocol GI-04
- Day 81 Patient accepted — Started GI-04 in the companion
- Day 89 No meaningful change — GI Support Protocol GI-04
What changed?
Trajectory began diverging from predicted response on Day 67.
Primary contributors, last 14 days
- GI instability+7
- Nutritional resilience+2
- Treatment adherence+2
What helped?
- Dietary Support Protocol NP-02Day 47Result: no meaningful change
- GI Support Protocol GI-04Day 80Result: no meaningful change
LIFE OS recommendation
Monitoring Escalation ME-01
83%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable26 min
improving · +6.4 vs previous 14 d
Sleep duration
Wearable6.7 h
stable · +0.1 vs previous 14 d
Energy level
Daily log3/10
improving · +0.5 vs previous 14 d
Steps
Wearable2,298
improving · +781 vs previous 14 d
GI burden
Companion58.9/100
improving · -5.3 vs previous 14 d
Adherence
Companion39.1 %
stable · -0.7 vs previous 14 d
Sleep quality
Wearable41.6/100
improving · +5.3 vs previous 14 d
Glucose, CGM daily mean
CGM147 mg/dL
stable · -5.5 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 21 from the failing basin, 67 from restoration.
Would help
- ME-01 Monitoring Escalation100% improved among 42 similar · onset 3 d · confidence 71%
- SC-12 Supportive Compound69% improved among 26 similar · onset 6 d · confidence 71%
- CR-01 Clinician Review100% improved among 6 similar · onset 5 d · confidence 71%
- More proteinGI -3 next day on high-intake days · n 17
Would not help
- GI-04 GI Support Protocolalready tried, no meaningful change
- NP-02 Dietary Support Protocolalready tried, no meaningful change
- Keep fat lowGI +2.9 next day on high-intake days · n 25
- Keep histamine lowGI +2.7 next day on high-intake days · n 21
- Keep ultra-processed lowGI +2.6 next day on high-intake days · n 19
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-3supporter · 95%
- Dietary fat load+2.9detractor · 95%
- Histamine load+2.7detractor · 95%
- Ultra-processed food+2.6detractor · 95%
- Alcohol+2.1detractor · 89%
- Simple carbohydrates+1no signal · 40%
- Insoluble fibre+0.5no signal · 16%
- Caffeine-0.2no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 59 and rising
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 44/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↓70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 60
- Autonomic recovery ↓45
- WearableResting HR 83 bpm
- Wearable2,298 steps/day
- Drug metabolism and exposure ↑20
- BloodToxicity index 55
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.2 · butyrate capacity 44/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 41 ms
- Sleep
- 6.9 h
- Steps
- 2,626
- Resting HR
- 82 bpm
Daily log: GI score 59, nutritional resilience 42, adherence 39.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02535 | 56% | S14 | SC-12 | improved | 50 |
| P-02039 | 55% | S14 | — | — | 38 |
| P-02348 | 54% | S14 | GI-04 | improved | 49 |
| P-02657 | 54% | S14 | — | — | 42 |
| P-02268 | 52% | S14 | GI-04 | improved | 43 |
| P-02574 | 52% | S14 | ME-01 | improved | 45 |
| P-02670 | 52% | S14 | SC-12 | improved | 45 |
| P-02320 | 51% | S14 | NP-02 | improved | 50 |
| P-02546 | 51% | S20 | NP-02 | improved | 40 |
| P-02693 | 51% | S14 | ME-01 | improved | 41 |
| P-02326 | 50% | S18 | NP-02 | improved | 44 |
| P-02363 | 50% | S14 | GI-04 | improved | 49 |